James Peyer Sells 3,507 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 3,507 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $7.96, for a total value of $27,915.72. Following the completion of the transaction, the insider owned 155,142 shares in the company, valued at approximately $1,234,930.32. This trade represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

James Peyer also recently made the following trade(s):

• On Monday, December 8th, James Peyer sold 3,105 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $8.59, for a total value of $26,671.95.
• On Friday, December 5th, James Peyer sold 16,295 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $11.50, for a total value of $187,392.50.
• On Thursday, December 4th, James Peyer sold 5,000 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $9.06, for a total transaction of $45,300.00.

Sensei Biotherapeutics Price Performance

Shares of SNSE traded up $0.70 on Wednesday, reaching $8.67. The company’s stock had a trading volume of 41,996 shares, compared to its average volume of 62,977. The stock has a market capitalization of $10.92 million, a P/E ratio of -0.45 and a beta of 0.32. The stock’s 50 day simple moving average is $9.86 and its two-hundred day simple moving average is $8.63. Sensei Biotherapeutics, Inc. has a 12-month low of $5.00 and a 12-month high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, November 14th. The company reported ($3.62) EPS for the quarter, beating analysts’ consensus estimates of ($4.11) by $0.49. Analysts expect that Sensei Biotherapeutics, Inc. will post -1.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SNSE has been the topic of a number of recent research reports. HC Wainwright cut Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, October 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Sensei Biotherapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.